Peripheral Artery Disease

Peripheral artery disease (PAD) involves atherosclerosis mainly in the extremities, especially in the legs and feet that lead to ischemia. Untreated, PAD can progress to critical limb ischemia (CLI), also called chronic limb-threatening ischemia (CLTI), which will lead to foot or leg amputation. The mortality rate for these CLI amputees is 70% within three years. There is currently an epidemic of PAD and CLI in the U.S. The majority of patients are defined by health disparities concentrated in the Black, Latino, Native American populations in both rural and low-income urban areas. A large number of PAD patients have other comorbities, with diabetes being one a primary issue.

On the frontline of the epidemic of peripheral artery disease (PAD) and related 400 leg amputations per day in the U.S., Kumar Madassery, MD, director of peripheral vascular intervention and critical limb ischemia (CLI) program at Rush University Medical Center in Chicago, explains there is a glaring health inequities in rural and low income areas of the country.

Peripheral artery disease is out of control in many rural, low income communities

Peripheral artery disease (PAD) leads to more than 400 leg amputations per day in the U.S. Kumar Madassery, MD, discussed the importance of increasing awareness and reaching patients before it is too late. 

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Radial access shows potential to ‘revolutionize’ care for peripheral artery disease

Radial access provides interventional cardiologists with a safe, effective alternative to femoral access during peripheral artery interventions.

money business cash flow dollar

Cordis finalizes deal to acquire MedAlliance for up to $1.1B

The total value of the acquisition, first announced in 2022, is dependent on various regulatory and commercial milestones.

Medtronic has received FDA approval for its IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

FDA says treating PAD with paclitaxel-coated devices does not increase mortality risk

After warning healthcare providers about a heightened risk of mortality back in 2019, the FDA has now updated its stance on the use of these devices. 

The Surmodics Pounce Thrombectomy System

FDA clears new ‘grab-and-go’ interventional device for below-the-knee blood clot removal

The new device was designed to remove thrombi and emboli from peripheral arteries ranging from 2 to 4 mm. 

Thumbnail

Marijuana use linked to much higher risk of peripheral artery disease

New research presented at SCAI Scientific Sessions 2023 suggests that marijuana users should understand the early warning signs of PAD, including feelings of pain and coldness in the leg. 

Thumbnail

Why women with peripheral artery disease are underdiagnosed, have worse outcomes

Using the World Health Organization’s model for analyzing gender-related healthcare needs, the authors of a new analysis aimed to explore disparities in PAD outcomes.